Management of eGFR 40 mL/min/1.73 m²

Classification and Risk Stratification

• An eGFR of 40 mL/min/1.73 m² indicates Stage G3b chronic kidney disease (CKD), representing moderately to severely decreased kidney function, according to the American Diabetes Association 1
• This level of renal function is associated with increased cardiovascular disease risk, CKD progression risk, and mortality, as stated by the American Diabetes Association 2

Mandatory Screening for CKD Complications

• When eGFR is <60 mL/min/1.73 m², screen for blood pressure monitoring, volume status, electrolyte abnormalities, metabolic acidosis, anemia, and mineral bone disease every 6-12 months for Stage 3 CKD, as recommended by the American Diabetes Association 2, 1

Medication Management

• Verify dosing of all medications, as many require adjustment when eGFR <60 mL/min/1.73 m², according to the American Diabetes Association 2
• NSAIDs should be strictly avoided, as they reduce renal blood flow and can precipitate acute kidney injury, as stated by the American Diabetes Association 2, 3

Blood Pressure and Proteinuria Management

• Measure urine albumin-to-creatinine ratio (UACR) annually to assess for albuminuria, and use ACE inhibitor or ARB as first-line antihypertensive therapy if albuminuria is present, as recommended by the American Diabetes Association 1, 4
• Target blood pressure <130/80 mmHg, and monitor serum creatinine and potassium after initiating therapy, according to the American Diabetes Association 2, 1

Glycemic Control

• Target A1C of 7% to delay CKD progression, and intensive glucose control has been shown to delay onset and progression of albuminuria and reduce eGFR decline in both type 1 and type 2 diabetes, as stated by the American Diabetes Association 1, 2

Dietary and Lifestyle Modifications

• Limit dietary protein to approximately 0.8 g/kg body weight per day, and restrict sodium to <2 g/day to reduce blood pressure and maximize diuretic effectiveness if needed, as recommended by the American Diabetes Association 4, 3

Nephrology Referral Criteria

• Refer promptly to nephrology if uncertainty about etiology of kidney disease, difficult management issues, or rapidly progressing kidney disease are present, as stated by the American Diabetes Association 4, 3

Monitoring Frequency

• Measure eGFR and UACR at least annually, and laboratory monitoring for complications every 6-12 months for Stage 3 CKD, as recommended by the American Diabetes Association 1, 4

Vaccination

• Hepatitis B vaccination is indicated early in patients likely to progress to end-stage kidney disease, according to the American Diabetes Association 2, 1

Critical Pitfalls to Avoid

• Do not overlook cardiovascular risk, as CKD at this stage markedly increases cardiovascular disease risk, requiring aggressive risk factor modification, as stated by the American Diabetes Association 2

Management of eGFR 40 mL/min/1.73 m² with Focus on Medication and Dietary Adjustments

Critical Medication Management

• For gout management at an eGFR level of 40 mL/min/1.73 m², the American College of Rheumatology recommends allopurinol maximum dosage should be adjusted to creatinine clearance; if uric acid target cannot be achieved, switch to febuxostat or benzbromarone with or without allopurinol, as suggested by the Annals of the Rheumatic Diseases 5

Dietary Modifications

• The National Kidney Foundation suggests limiting dietary protein to approximately 0.8 g/kg body weight per day and restricting sodium to <2 g/day to reduce hyperfiltration injury and slow progression, as supported by Kidney International 6

Diagnostic Considerations

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering cystatin C-based eGFR or measured GFR if creatinine-based estimates seem discordant with clinical picture, as noted in Kidney International 7

Management of Chronic Kidney Disease with Low eGFR

Classification and Screening

• The National Kidney Foundation recommends that an eGFR of 30-44 mL/min/1.73 m² carries increased risk for cardiovascular disease, CKD progression, and mortality, and if eGFR is 45-59 mL/min/1.73 m² without albuminuria or other markers of kidney damage, consider measuring cystatin C to confirm CKD diagnosis 8
• The Kidney International guideline suggests measuring serum calcium and phosphorus every 3-6 months in Stage G3b, and measure PTH every 6-12 months in Stage G3b 9

Nephrology Referral and Hepatorenal Syndrome

• The American Journal of Transplantation recommends referring promptly to nephrology if there is uncertainty about etiology of kidney disease, difficult management issues, or rapidly progressing kidney disease, and the combination of bilirubinuria and low eGFR suggests potential hepatorenal syndrome, drug-induced liver and kidney injury, or systemic disease affecting both organs, warranting specialist evaluation 10

Management of Stage G3b Chronic Kidney Disease (eGFR ≈ 41 mL/min/1.73 m²)

Diagnosis Confirmation and Monitoring

• Repeat the estimated glomerular filtration rate (eGFR) measurement within 3 months to verify chronicity, because CKD is defined by persistent abnormalities for ≥ 3 months. [@1]
• Do not rely on serum creatinine alone; always calculate and use eGFR for assessment of kidney function. [@1]

Use of Alternative Filtration Markers

• When the creatinine‑based eGFR appears discordant with the clinical picture, measure cystatin C‑based eGFR; creatinine estimates are inaccurate in ≈ 16‑20 % of individuals with eGFR < 60 mL/min/1.73 m². [@2]

Nutritional Recommendations

• Limit dietary protein to 0.8 g per kilogram body weight per day to reduce hyperfiltration injury and slow CKD progression in patients with eGFR 30‑44 mL/min/1.73 m². [@3]
• This protein target is lower than the 1.2‑1.5 g/kg/day recommended for patients with eGFR 30‑59 mL/min/1.73 m² who do not have severe impairment, underscoring the importance of the 30 mL/min/1.73 m² threshold. [@3]

Nephrology Referral Criteria

• Refer to nephrology when eGFR < 45 mL/min/1.73 m² (the patient with eGFR 41 mL/min/1.73 m² meets this criterion). [@4][@5]
• Refer when confirmed proteinuria is present, especially if urine albumin‑to‑creatinine ratio (UACR) ≥ 300 mg/g. [@4]
• Refer diabetic patients with pre‑existing CKD. [@4]
• Although mandatory referral is generally recommended at eGFR < 30 mL/min/1.73 m², earlier referral at eGFR ≈ 41 mL/min/1.73 m² is appropriate given the high‑risk features. [@4][@5]

Dialysis Initiation Considerations

These guidance points are based on longitudinal cohort analyses and expert consensus. [@6][@7]

Stage 3b Chronic Kidney Disease: Definition, Staging, and Clinical Implications

Definition & KDIGO Staging

• A glomerular filtration rate (eGFR) of 34 mL/min/1.73 m² classifies a patient as having Stage 3b chronic kidney disease, which is defined as moderately to severely decreased kidney function (eGFR 30‑44 mL/min/1.73 m²) according to KDIGO. 11, 12
• The KDIGO classification system stratifies chronic kidney disease by eGFR as follows:

Clinical Significance

• Stage 3b corresponds to loss of roughly two‑thirds of normal kidney function and is linked to substantially increased risks of adverse outcomes. 12
• Compared with earlier stages, Stage 3b is associated with markedly higher cardiovascular disease risk, faster CKD progression, and increased mortality. 11

Diagnostic Considerations

• Chronic kidney disease diagnosis requires persistent abnormalities for at least three months; a single eGFR measurement is insufficient. 12
• Serum creatinine concentration alone should not be used to assess kidney function; eGFR must be calculated using validated equations. 13, 12

Practical Pitfalls

• Underestimation of the severity of Stage 3b disease is a common error; despite being grouped under “stage 3,” Stage 3b carries significantly higher risks and warrants more aggressive monitoring and nephrology involvement. 11